

# ForPatients

*by Roche*

Multiple Sclerosis (MS)

## A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis

**Trial Status**

Active, not recruiting

**Trial Runs In**

1 Countries

**Trial Identifier**

NCT03972306 CN41144

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### *Trial Summary:*

This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple sclerosis (MS).

**Hoffmann-La Roche**

Sponsor

**Phase 1**

Phase

---

**NCT03972306 CN41144**

Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**

All

**Age**

>=18 Years & <= 65 Years

**Healthy Volunteers**

No

---